🍽️ guanabenz acetate,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Mechanism of Action: Guanabenz acetate belongs to a class of medications known as alpha-2 adrenergic agonists. It works by stimulating alpha-2 adrenergic receptors in the brainstem, leading to reduced sympathetic outflow from the central nervous system. This results in vasodilation (widening of blood vessels) and a subsequent decrease in blood pressure.

  2. Treatment of Hypertension: Guanabenz acetate is primarily indicated for the treatment of hypertension, particularly in patients who have not responded adequately to other antihypertensive medications. It is often used as a second- or third-line agent when first-line treatments are ineffective or poorly tolerated.

  3. Blood Pressure Lowering Effects: By reducing sympathetic activity and inducing vasodilation, guanabenz acetate helps to lower blood pressure. It can effectively control both systolic and diastolic blood pressure levels when used as part of a comprehensive treatment regimen.

  4. Limited Use: Guanabenz acetate is less commonly prescribed today compared to other antihypertensive medications due to several factors, including its side effect profile, dosing schedule, and the availability of newer and more effective agents.

  5. Adverse Effects: Guanabenz acetate can cause a range of side effects, some of which can be significant. Common side effects include drowsiness, dizziness, dry mouth, fatigue, weakness, headache, and gastrointestinal disturbances (such as nausea and constipation).

  6. Central Nervous System Effects: Guanabenz acetate can penetrate the blood-brain barrier and exert effects on the central nervous system. This may result in side effects such as sedation, drowsiness, or mental clouding. Patients should use caution when performing activities that require mental alertness, such as driving or operating machinery.

  7. Orthostatic Hypotension: Like other antihypertensive medications, guanabenz acetate can cause orthostatic hypotension, a sudden drop in blood pressure upon standing up from a sitting or lying position. Patients may experience symptoms such as dizziness, lightheadedness, or fainting.

  8. Cardiovascular Effects: Guanabenz acetate may affect heart rate and rhythm. It can cause bradycardia (slow heart rate) and may exacerbate conduction abnormalities in patients with pre-existing cardiac conditions. Patients with significant cardiac disease should be monitored closely while taking guanabenz acetate.

  9. Withdrawal Rebound Hypertension: Abrupt discontinuation of guanabenz acetate can lead to rebound hypertension, characterized by a sudden and significant increase in blood pressure. Therefore, the medication should be tapered off gradually under medical supervision when discontinuing treatment.

  10. Contraindications and Precautions: Guanabenz acetate is contraindicated in patients with hypersensitivity to the medication, severe bradycardia, heart block, or pheochromocytoma (a rare adrenal gland tumor). It should be used with caution in patients with pre-existing cardiovascular disease, renal impairment, or hepatic impairment.

  11. Interactions with Other Medications: Guanabenz acetate may interact with other medications that affect blood pressure or central nervous system function. Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking before starting guanabenz acetate.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of guanabenz acetate,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces

Bacteria Impacted by guanabenz acetate,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Phocaeicola genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Akkermansia genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Agathobacter genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Coprococcus comes species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of guanabenz acetate,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0 0
ADHD 0.8 0.2 3
Allergic Rhinitis (Hay Fever) 0.5 0.5
Allergies 0.3 -0.3
Allergy to milk products 0.5 0.5
Alzheimer's disease 0.5 1 -1
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.6 0.2 2
Ankylosing spondylitis 0.4 -0.4
Anorexia Nervosa 0.5 -0.5
Antiphospholipid syndrome (APS) 0 0
Asthma 0.1 0.7 -6
Atherosclerosis 0.2 -0.2
Atrial fibrillation 0.6 0.4 0.5
Autism 2.5 2 0.25
Bipolar Disorder 0.4 0.2 1
Brain Trauma 0.4 -0.4
Carcinoma 0.4 0.4 0
Celiac Disease 1.3 0.5 1.6
Cerebral Palsy 0.2 0.4 -1
Chronic Fatigue Syndrome 1.5 1.9 -0.27
Chronic Kidney Disease 0.6 0.3 1
Chronic Lyme 0.4 -0.4
Chronic Obstructive Pulmonary Disease (COPD) 0.2 -0.2
Chronic Urticaria (Hives) 0.1 0.2 -1
Colorectal Cancer 0.4 0 0
Constipation 1.3 1.3
Coronary artery disease 0 0.2 0
COVID-19 1.4 2.7 -0.93
Crohn's Disease 1.5 0.8 0.88
cystic fibrosis 0.4 -0.4
Depression 1.9 1.5 0.27
Eczema 0.1 -0.1
Endometriosis 0.6 0 0
Epilepsy 0.5 0.7 -0.4
Fibromyalgia 0.1 1.6 -15
Functional constipation / chronic idiopathic constipation 1.4 0.9 0.56
gallstone disease (gsd) 0.1 0.1
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.9 0.9
Generalized anxiety disorder 0.7 -0.7
giant cell arteritis 0.1 -0.1
Gout 0.2 -0.2
Graves' disease 0.4 0.4
Halitosis 0.4 0.4
Hashimoto's thyroiditis 0.7 0.4 0.75
Hidradenitis Suppurativa 0 0
Histamine Issues,Mast Cell Issue, DAO Insufficiency 0.9 0.1 8
hypercholesterolemia (High Cholesterol) 0.1 0.2 -1
hyperglycemia 0.7 -0.7
Hyperlipidemia (High Blood Fats) 0.1 0.1
hypersomnia 0 0
hypertension (High Blood Pressure 0.5 0.7 -0.4
Hypothyroidism 0.2 -0.2
Hypoxia 0.5 0.5
IgA nephropathy (IgAN) 0.9 -0.9
Inflammatory Bowel Disease 0.4 1.1 -1.75
Insomnia 0.4 0.4 0
Intelligence 1 1
Intracranial aneurysms 0.4 0.4
Irritable Bowel Syndrome 0.7 2.3 -2.29
Liver Cirrhosis 0.8 0.8 0
Long COVID 2.1 0.7 2
Low bone mineral density 0.2 -0.2
Lung Cancer 0.2 -0.2
ME/CFS with IBS 0.3 0.8 -1.67
ME/CFS without IBS 0.2 0.4 -1
Metabolic Syndrome 0.8 2.7 -2.38
Mood Disorders 2.5 1.5 0.67
multiple chemical sensitivity [MCS] 0.1 0.1
Multiple Sclerosis 0.3 0.7 -1.33
Multiple system atrophy (MSA) 0.3 0.3
Neuropathy (all types) 0.1 0.1
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.1 0.9 -8
Obesity 1 0.9 0.11
obsessive-compulsive disorder 2.1 1 1.1
Osteoarthritis 0.5 0.5
Osteoporosis 0.5 0.6 -0.2
Parkinson's Disease 0.5 0.3 0.67
Polycystic ovary syndrome 1.4 0.2 6
Postural orthostatic tachycardia syndrome 0.1 0.2 -1
primary biliary cholangitis 0.7 -0.7
Psoriasis 0.2 0.8 -3
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.7 0.7 0
Rosacea 0.2 0.1 1
Schizophrenia 1.8 0.3 5
scoliosis 0.2 0 0
Sjögren syndrome 1.1 -1.1
Sleep Apnea 0.2 0.6 -2
Stress / posttraumatic stress disorder 0.6 0.8 -0.33
Systemic Lupus Erythematosus 0.6 0 0
Tic Disorder 0.9 0.9
Tourette syndrome 0.1 0.4 -3
Type 1 Diabetes 1.5 1 0.5
Type 2 Diabetes 1.6 2.6 -0.63
Ulcerative colitis 0.5 2.7 -4.4
Unhealthy Ageing 1.9 0.4 3.75

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.